Half Year 2026 Biomerieux SA Earnings Call Transcript
Key Points
- BioMerieux SA (BMXMF) reported a sales growth acceleration in Q2 2026, with a 5% increase, and 7.3% growth excluding respiratory panel sales.
- The company generated nearly EUR 300 million in free cash flow in H1 2026, marking a 76% increase compared to H1 2025.
- BioMerieux SA (BMXMF) maintained a strong focus on innovation with multiple product launches, including the revised BioFire gastrointestinal panel and the SpinChip immunoassay platform.
- The company achieved a 31% reduction in greenhouse gas emissions by the end of June 2026, aligning with its sustainability objectives.
- BioMerieux SA (BMXMF) reported strong performance in industrial applications, with a 9% growth in CSOs and double-digit growth in reagents.
- The company's CBITS declined by 5% organically in H1 2026, reflecting modest sales evolution in Q1.
- BioMerieux SA (BMXMF) experienced a 6% decline in BioFire respiratory panels, with price erosion impacting sales.
- The Asia Pacific region saw a 3% decline, with China down 6% and negative trends in Japan due to regulatory changes.
- The company's gross profit margin decreased by 70 basis points on an organic basis, affected by an unfavorable product mix and increased manufacturing costs.
- BioMerieux SA (BMXMF) revised its financial perspectives for 2027 and 2028, adjusting sales growth expectations to 3% to 6% annually, reflecting a slower market growth than initially anticipated.
Hello and welcome to the BioMario Half Year 2026 Financial Performance Call. Please note this webcast is being recorded and for the first part participants lines will be in listen-only mode. You will have the opportunity to ask questions at the end of the presentation. This can be done by pressing pound key 5 on your telephone keypad. I will now hand the conference. Over to Emeric Fichet, Head of Investor Relations.
Thank you. Hello, everyone. Good afternoon and thank you for joining this call. I am with Pierre Boulou, CEO, together with Guillaume Bourre, CFO.
Please note that this conference call will include forward-looking statements that may change or be modified due to uncertainties and risks related to the company's environment. Accordingly, we cannot give any assurance as to whether we will achieve this objective.
I also remind you that today's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
